Digital scanning technology halves need for liver biopsies

Researches from the University of Birmingham and University of Edinburgh have cut the number of liver biopsies performed on patients with fatty liver in half by using a non-invasive digital image scan. Findings were published in Alimentary Pharmacology & Therapeutics.

In this study, researchers examined the feasibility and accuracy of the LiverMultiScan non-invasive digital imaging system in identifying patients with fatty liver disease and eliminating the need for liver biopsies.

"It is clear that there is a rising burden of liver disease, particularly from non-alcoholic fatty liver disease. Our study is of importance to evaluating the best pathways to offer patients who need evaluation of their liver health,” said Gideon Hirschfield, with the University of Birmingham. "Whilst liver biopsy remains an important part of advanced Hepatology practice, clearly we need better non-invasive tools at our disposal to evaluate the nature and severity of liver disease.

A total of 50 patients and six volunteers received digital image scanning. Results were then processed by clinical imaging specialists. Results showed the LiverMultiScan was more effective in grading disease severity and excluding patients at increased risk of disease progression than other tests. In conclusion, researchers noted that 458 of every 1,000 liver biopsies could be avoided by utilizing the digital scan and save around $200,000 per 1,000 patients.

"Non-alcoholic fatty liver disease is on the increase - the prevalence is estimated at around 20-30% in the UK,” said Philip Newsome, director of the University of Birmingham's Centre for Liver Research. "As numbers are expected to grow, this will undoubtedly have a major impact on the nation's health, and will place a significant demand on NHS resources. The rising burden of non-alcoholic fatty liver disease calls for simpler and low risk strategies to manage this clinical problem that meet the needs of both clinicians and patients."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.